CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)

VIENNA, Va. -- CEL-SCI Corporation (NYSE AMEX: CVM) today announced that the Chinese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine® (Leukocyte Interleukin, Injection)*. The patent, Chinese patent number ZL200480025403.6, is titled, “A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture”.

The bad news was eliminating suboptimal practices would involve reorganization, relocation of personnel, revamping of procedures, policies and paperwork, plus a mindset change regarding how managers and employees involved in the front-end process would do their jobs.Senior Medical Physicists, Dr. Gino Fallone and Brad Murray, and the associated research team at Alberta Health Services' Cross Cancer Institute and University of Alberta's Department of Oncology were the first in the world to merge the capabilities of an MRI scanner with a linear accelerator, or LINAC, in 2008 with development of a head-size prototype. The merging allows for more accurate treatment of cancer tumours. The combination of existing technologies quickens the regulatory pathway to commercialization of the new treatment device.WD Toll-Free Number: 1 888 338-WEST (9378)"To meet the goal of delivering the highest possible value to customers, we had to go beyond delivering a quality part at a good price. We had to move work faster than we ever had before," said McAteer.The U of A and Cross Cancer Institute have a reputation as leaders in the field of medical physics and radiotherapy that will be further enhanced by this project, leading to economic benefits for Alberta through the continued growth of internationally recognized expertise in specialized medical equipment.After three months, Vulcan cut front-end processing time in half. McAteer has put together a checklist of the specific steps Vulcan took to address customer demand for shorter cycle times. A copy of the checklist, "Vulcan's 5 Steps to One-Day Order Entry" is available for downloading on the company's website. ( Click here .)* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval."The technique is quite simple," said Vulcan's Materials Manager Curt McAteer. "Set an outsized goal, in this case acknowledging customer orders within 24 hours, and then eliminate or correct everything that gets in the way of that goal."

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2010. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.